aidsВИЧ-инфекция и иммуносупрессииHIV Infection and Immunosuppressive Disorders2077-9828Baltic Medical Education Center10.22328/2077-9828-2017-9-2-7-15aids-254Research ArticleАНАЛИТИЧЕСКИЙ ОБЗОРANALYTICAL REVIEWНАРУШЕНИЯ ФУНКЦИОНАЛЬНОГО СОСТОЯНИЯ СИСТЕМЫ КРОВЕТВОРЕНИЯ У БОЛЬНЫХ С ВИЧ-ИНФЕКЦИЕЙDISORDERS OF HEMOPOIESIS IN HIV PATIENTSКанестриВ. Г.KanestriV. G.

Канестри Вероника Геннадиевна — доктор медицинских наук, старший научный сотрудник. СНИО ЭП СПИД

105275, Москва, 8-я ул. Соколиной горы, 15, корп. 2

kanestri@yandex.ruФБУН «Центральный научно-исследовательский институт эпидемиологии» РоспотребнадзораРоссияCentral Research Institute of EpidemiologyRussian Federation20170707201792715Copyright © Канестри В.Г., 20172017Канестри В.Г.Kanestri V.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://hiv.bmoc-spb.ru/jour/article/view/254

В данном обзоре представлены основные патологические состояния системы кроветворения, возникающие у больных, инфицированных вирусом иммунодефицита человека, которые связаны как с основным заболеванием, так и со вторичными и сопутствующими заболеваниями (вирусными гепатитами, микобактериальной, герпесвирусной, цитомегаловирусной инфекциями, пневмоцистной пневмонией, грибковыми и онкологическими заболеваниями), а также целым рядом лекарственных препаратов, часто применяемых у этой категории больных. В статье описаны возможные механизмы гематологических нарушений, наиболее адекватные и полные методы диагностики самих нарушений и причин, их вызвавших. Рассмотрены основные клинические симптомы, сопровождающие эти состояния, а также изложены возможные пути и варианты коррекции. В публикации использованы данные когортных, крупных рандомизированных международных исследований и результаты, полученные отечественными авторами.

This review presents the main pathological conditions of the hematopoietic system that occur in patients with HIV infection, which are associated with both the main disease and secondary diseases and comorbidity (viral hepatitis, mycobacterial, herpes, cytomegalovirus infections, pneumocystis pneumonia, fungal and oncological diseases), as well as a number of medications often used in this category of patients. The article describes possible mechanisms of hematological disorders, the most adequate and complete methods for diagnosing this disorders and the causes of them. The main clinical symptoms accompanying these conditions are considered, as well as possible ways and variants of correction. The publication uses data from cohort, large randomized international studies and results obtained by domestic authors.

ВИЧ-инфекцияантиретровирусная терапиягематологические нарушенияHIV infectionantiretroviral therapyhematological disorders.ReferencesХоффман К., Рокштро Ю.К. Лечение ВИЧ-инфекции 2011. М.: Р.Валент, 2012. 736 с. [Hoffman K., Rockstroh Yu.K. Treatment of HIV infec- tion 2011. Moscow: R.Valent, 2012, 736 р. (In Russ.)].Хоффман К., Рокштро Ю.К. Лечение ВИЧ-инфекции 2011. М.: Р.Валент, 2012. 736 с. [Hoffman K., Rockstroh Yu.K. Treatment of HIV infec- tion 2011. Moscow: R.Valent, 2012, 736 р. (In Russ.)].Бартлетт Дж., Галлант Дж., Фам П. Клинические аспекты ВИЧ-инфекции. 2012. М.: Р.Валент, 2012. 528 с. [Bartlett J., Gallant J., Pham P. Clinical aspects of HIV infection. 2012. Moscow: R.Valent, 2012, 528 р. (In Russ.)].Бартлетт Дж., Галлант Дж., Фам П. Клинические аспекты ВИЧ-инфекции. 2012. М.: Р.Валент, 2012. 528 с. [Bartlett J., Gallant J., Pham P. Clinical aspects of HIV infection. 2012. Moscow: R.Valent, 2012, 528 р. (In Russ.)].Semba R.D., Shah N., Klein R.S. Prevalence and cumulative incidence of and risk factors for anemia in a multicenter cohort study of human immu- nodeficiency virus-infected and -uninfected women. Clin. Infect. Dis., 2002, Vol. 34 (2), рр. 260–266.Semba R.D., Shah N., Klein R.S. Prevalence and cumulative incidence of and risk factors for anemia in a multicenter cohort study of human immu- nodeficiency virus-infected and -uninfected women. Clin. Infect. Dis., 2002, Vol. 34 (2), рр. 260–266.Шиффман Ф.Дж. Патофизиология крови. М.; СПб.: БИНОМ; Невский диалект, 2000. 448 с. [Shiffman F.J. Pathophysiology of blood.Шиффман Ф.Дж. Патофизиология крови. М.; СПб.: БИНОМ; Невский диалект, 2000. 448 с. [Shiffman F.J. Pathophysiology of blood.Moscow; Saint-Petersburg: BINOM; Nevsky dialect, 2000, 448 p. (In Russ.)].Moscow; Saint-Petersburg: BINOM; Nevsky dialect, 2000, 448 p. (In Russ.)].Виноградов А.В. Дифференциальный диагноз внутренних болезней. М.: Медицина, 1980. 816 с. [Vinogradov A.V. Differential diagnosis of internal diseases. Moscow: Мedicine, 1980, 816 р. (In Russ.)].Виноградов А.В. Дифференциальный диагноз внутренних болезней. М.: Медицина, 1980. 816 с. [Vinogradov A.V. Differential diagnosis of internal diseases. Moscow: Мedicine, 1980, 816 р. (In Russ.)].Moses A.V., Williams S., Heneveld M.L. Human immunodeficiency virus infection of bone marrow endothelium reduces induction of stromal hematopoietic growth factors. Blood, 1996, Vol. 87 (3), рр. 919–925.Moses A.V., Williams S., Heneveld M.L. Human immunodeficiency virus infection of bone marrow endothelium reduces induction of stromal hematopoietic growth factors. Blood, 1996, Vol. 87 (3), рр. 919–925.Zhang Y., Harada A., Bluethmann H., Wang J.B. Tumor necrosis factor (TNF) is a physiologic regulator of hematopoietic progenitor cells: increa- se of early hematopoietic progenitor cells in TNF receptor p55-deficient mice in vivo and potent inhibition of progenitor cell proliferation by TNF alpha in vitro. Blood, 1995, Vol. 86 (8), рр. 2930–2937.Zhang Y., Harada A., Bluethmann H., Wang J.B. Tumor necrosis factor (TNF) is a physiologic regulator of hematopoietic progenitor cells: increa- se of early hematopoietic progenitor cells in TNF receptor p55-deficient mice in vivo and potent inhibition of progenitor cell proliferation by TNF alpha in vitro. Blood, 1995, Vol. 86 (8), рр. 2930–2937.Sullivan P.S., Hanson D.L., Chu S.Y. et al. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood, 1998, Vol. 91, рр. 301–308.Sullivan P.S., Hanson D.L., Chu S.Y. et al. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood, 1998, Vol. 91, рр. 301–308.Najean Y., Rain J.D. The mechanism of thrombocytopenia in patients with HIV. J. Lab. Clin. Med., 1994, Vol. 123, рр. 415–420.Najean Y., Rain J.D. The mechanism of thrombocytopenia in patients with HIV. J. Lab. Clin. Med., 1994, Vol. 123, рр. 415–420.ВИЧ-инфекция и СПИД: национальное руководство / Под ред. В.В.Покровского. М.: ГЭОТАР-Медиа, 2013. 608 с. [HIV infection and AIDS: national manual. Еd. V.V.Pokrovsky. Moscow: GEOTAR-Media, 2013, 608 p. (In Russ.)].ВИЧ-инфекция и СПИД: национальное руководство / Под ред. В.В.Покровского. М.: ГЭОТАР-Медиа, 2013. 608 с. [HIV infection and AIDS: national manual. Еd. V.V.Pokrovsky. Moscow: GEOTAR-Media, 2013, 608 p. (In Russ.)].Scadden D.T., Zon L.I., Groopman J.E. Pathophysiology and management of HIV-associated hematologic disorders. Blood, 1989, Vol. 74 (5), рр. 1455–1463.Scadden D.T., Zon L.I., Groopman J.E. Pathophysiology and management of HIV-associated hematologic disorders. Blood, 1989, Vol. 74 (5), рр. 1455–1463.Remacha A.F., Cadafalch J. Cobalamin deficiency in patients infected with the human immunodeficiency virus. Semin. Hematol., 1999, Vol. 36, No. 1, рр. 75–87.Remacha A.F., Cadafalch J. Cobalamin deficiency in patients infected with the human immunodeficiency virus. Semin. Hematol., 1999, Vol. 36, No. 1, рр. 75–87.World Health Organization. Iron deficiency anaemia: assessment, prevention, and control. A guide for programme managers. Geneva: World Health Organization, 2001 (WHO/NHD/01.3), 114 p.World Health Organization. Iron deficiency anaemia: assessment, prevention, and control. A guide for programme managers. Geneva: World Health Organization, 2001 (WHO/NHD/01.3), 114 p.Moore R.D. Human immunodeficiency virus infection, anemia, and survival. Clin. Infect. Dis., 1999, Vol. 29 (1), рр. 44–49.Moore R.D. Human immunodeficiency virus infection, anemia, and survival. Clin. Infect. Dis., 1999, Vol. 29 (1), рр. 44–49.Mocroft A., Ledergerber B., Katlama C. et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet, 2003, Vol. 362, рр. 22–29.Mocroft A., Ledergerber B., Katlama C. et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet, 2003, Vol. 362, рр. 22–29.Harris R.J., Sterne J.A., Abgrall S. Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir. Ther., 2008, Vol. 13 (8), рр. 959–967.Harris R.J., Sterne J.A., Abgrall S. Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir. Ther., 2008, Vol. 13 (8), рр. 959–967.Fangman J.J., Scadden D.T. Anemia in HIV-infected adults: epidemiology, pathogenesis, and clinical management. Curr. Hematol. Rep., 2005, Vol. 4 (2), рр. 95–102.Fangman J.J., Scadden D.T. Anemia in HIV-infected adults: epidemiology, pathogenesis, and clinical management. Curr. Hematol. Rep., 2005, Vol. 4 (2), рр. 95–102.Исследование системы крови в клинической практике / Под ред. Г.И.Козинца и В.А. Макарова. М.: Триада-Х, 1997. 480 с. [The study of the blood system in clinical practice. Еd. G.I. Kozinets and V.A.Makarov. Moscow: Тriada-Х, 1997, 480 р. (In Russ.)].Исследование системы крови в клинической практике / Под ред. Г.И.Козинца и В.А. Макарова. М.: Триада-Х, 1997. 480 с. [The study of the blood system in clinical practice. Еd. G.I. Kozinets and V.A.Makarov. Moscow: Тriada-Х, 1997, 480 р. (In Russ.)].Jacobson M.A., Liu R.C., Davies D. Human immunodeficiency virus disease-related neutropenia and the risk of hospitalization for bacterial infec- tion. Arch. Int. Med., 1997, Vol. 157 (16), рр. 1825–1831.Jacobson M.A., Liu R.C., Davies D. Human immunodeficiency virus disease-related neutropenia and the risk of hospitalization for bacterial infec- tion. Arch. Int. Med., 1997, Vol. 157 (16), рр. 1825–1831.Moore D.A., Benepal T., Portsmouth S. et al. Etiology and natural history of neutropenia in human immunodeficiency virus disease: a prospective study. Clin. Infect. Dis., 2001, Vol. 32 (3), рр. 469–475.Moore D.A., Benepal T., Portsmouth S. et al. Etiology and natural history of neutropenia in human immunodeficiency virus disease: a prospective study. Clin. Infect. Dis., 2001, Vol. 32 (3), рр. 469–475.Glatt A.E., Anand A. Thrombocytopenia in patients infected with human immunodeficiency virus: treatment update. Clin. Infect. Dis., 1995, Vol. 21, рр. 415–423.Glatt A.E., Anand A. Thrombocytopenia in patients infected with human immunodeficiency virus: treatment update. Clin. Infect. Dis., 1995, Vol. 21, рр. 415–423.Малеев В.В., Полякова А.М., Кравченко А.В. Нарушения гемостаза при инфекционных заболеваниях. М.: ДеНово, 2004. 160 с. [Maleev V.V., Polyakov A.M., Kravchenko A.V. Disorders of hemostasis in infectious diseases. Moscow: DeNovo, 2004, 160 p. (In Russ.)].Малеев В.В., Полякова А.М., Кравченко А.В. Нарушения гемостаза при инфекционных заболеваниях. М.: ДеНово, 2004. 160 с. [Maleev V.V., Polyakov A.M., Kravchenko A.V. Disorders of hemostasis in infectious diseases. Moscow: DeNovo, 2004, 160 p. (In Russ.)].Arranz Caso J.A., Mingo C.S., Tena J.G. Effect of highly active antiretroviral therapy on thrombocytopenia in patients with HIV infection. N. Engl. J. Med., 1999, Vol. 341, рр. 1239–1240.Arranz Caso J.A., Mingo C.S., Tena J.G. Effect of highly active antiretroviral therapy on thrombocytopenia in patients with HIV infection. N. Engl. J. Med., 1999, Vol. 341, рр. 1239–1240.Huang S.S., Barbour J.D., Deeks S.G. et al. Reversal of human immunodeficiency virus type 1–associated hematosuppression by effective anti- retroviral therapy. Clin. Infect. Dis., 2000, Vol. 30, рр. 504–510.Huang S.S., Barbour J.D., Deeks S.G. et al. Reversal of human immunodeficiency virus type 1–associated hematosuppression by effective anti- retroviral therapy. Clin. Infect. Dis., 2000, Vol. 30, рр. 504–510.George J.N., Woolf S.H., Raskob G.E. et al. Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology. Blood, 1996, Vol. 88, рр. 3–40.George J.N., Woolf S.H., Raskob G.E. et al. Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology. Blood, 1996, Vol. 88, рр. 3–40.Канестри В.Г., Кравченко А.В. Гематологические нарушения у больных ВИЧ-инфекцией, получающих антиретровирусную терапию // ВИЧ-инфекция и иммуносупрессии. 2013. Т. 5, № 3. С. 63–70. [Kanestri V.G., Kravchenko A.V. Hematologic abnormalities in HIV-infected patients on antiretroviral therapy. HIV Infection and Immunosuppressive Disorders, 2013, Vol. 5, No. 3, рр. 63–70 (In Russ.)].Канестри В.Г., Кравченко А.В. Гематологические нарушения у больных ВИЧ-инфекцией, получающих антиретровирусную терапию // ВИЧ-инфекция и иммуносупрессии. 2013. Т. 5, № 3. С. 63–70. [Kanestri V.G., Kravchenko A.V. Hematologic abnormalities in HIV-infected patients on antiretroviral therapy. HIV Infection and Immunosuppressive Disorders, 2013, Vol. 5, No. 3, рр. 63–70 (In Russ.)].Koch M.A., Volberding P.A., Lagakos S.W. et al. Toxic effect of zidovudine in asymptomatic human immunodeficiency virus-infected individuals with CD4 cell count of 0,50x109/L or less. Arch. Int. Med., 1992, Vol. 152, рр. 1992.Koch M.A., Volberding P.A., Lagakos S.W. et al. Toxic effect of zidovudine in asymptomatic human immunodeficiency virus-infected individuals with CD4 cell count of 0,50x109/L or less. Arch. Int. Med., 1992, Vol. 152, рр. 1992.Покровский В.В., Юрин О.Г., Кравченко А.В. Национальные рекомендации по диспансерному наблюдению и лечению больных ВИЧ-инфекцией. Клинический протокол // Эпидемиология и инфекционные болезни. Актуальные вопросы. 2016. № 6. 72 с. [Pokrovskiy V.V., Urin О.G., Кravchenko А.V. National guidelines for dispensary observation and treatment of patients with HIV infection. Clinical Protocol. Epidemiology and Infectious Diseases. The Actual Issues, 2016, No. 6, 72 р. (In Russ.)].Покровский В.В., Юрин О.Г., Кравченко А.В. Национальные рекомендации по диспансерному наблюдению и лечению больных ВИЧ-инфекцией. Клинический протокол // Эпидемиология и инфекционные болезни. Актуальные вопросы. 2016. № 6. 72 с. [Pokrovskiy V.V., Urin О.G., Кravchenko А.V. National guidelines for dispensary observation and treatment of patients with HIV infection. Clinical Protocol. Epidemiology and Infectious Diseases. The Actual Issues, 2016, No. 6, 72 р. (In Russ.)].De Jesus E., Herrera G., Teofilo E. et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin. Infect. Dis., 2004, Vol. 39, рр. 1038–1046.De Jesus E., Herrera G., Teofilo E. et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin. Infect. Dis., 2004, Vol. 39, рр. 1038–1046.Кравченко А.В., Канестри В.Г. Нуклеозидные ингибиторы обратной транскриптазы ВИЧ — препараты абакавир и ламивудин в схемах антиретровирусной терапии первой линии // Эпидемиология и инфекционные болезни. Актуальные вопросы. 2011. № 2. С. 49–55. [Kravchenko A.V., Kanestri V.G. Nucleoside reverse transcriptase inhibitors of the HIV drugs abacavir and lamivudine in antiretroviral therapy is first line. Epidemiology and Infectious Diseases. The Actual Issues, 2011, No. 2, pp. 49–55 (In Russ.)].Кравченко А.В., Канестри В.Г. Нуклеозидные ингибиторы обратной транскриптазы ВИЧ — препараты абакавир и ламивудин в схемах антиретровирусной терапии первой линии // Эпидемиология и инфекционные болезни. Актуальные вопросы. 2011. № 2. С. 49–55. [Kravchenko A.V., Kanestri V.G. Nucleoside reverse transcriptase inhibitors of the HIV drugs abacavir and lamivudine in antiretroviral therapy is first line. Epidemiology and Infectious Diseases. The Actual Issues, 2011, No. 2, pp. 49–55 (In Russ.)].Moore R.D. Anemia and human immunodeficiency virus disease in era of highly active antiretroviral therapy. Semin. Hematol., 2000, Vol. 37, рр. 18–23.Moore R.D. Anemia and human immunodeficiency virus disease in era of highly active antiretroviral therapy. Semin. Hematol., 2000, Vol. 37, рр. 18–23.Justice A.C., McGinnis K.A., Skanderson M. et al. Towards a combined prognostic index for survival in HIV infection: the role of ‘non-HIV’ bio- markers. HIV Med., 2010, Vol. 1, рр. 143–151.Justice A.C., McGinnis K.A., Skanderson M. et al. Towards a combined prognostic index for survival in HIV infection: the role of ‘non-HIV’ bio- markers. HIV Med., 2010, Vol. 1, рр. 143–151.Mocroft A., Kirk O., Barton S.E., Dietrich M. et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS, 1999, Vol. 13, рр. 943–950.Mocroft A., Kirk O., Barton S.E., Dietrich M. et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS, 1999, Vol. 13, рр. 943–950.Moyle G. Anaemia in persons with HIV infection: prognostic marker and contributor to morbidity. AIDS Rev., 2002, Vol. 4 (1), рр. 13–20.Moyle G. Anaemia in persons with HIV infection: prognostic marker and contributor to morbidity. AIDS Rev., 2002, Vol. 4 (1), рр. 13–20.Abrams D.I., Steinhart C., Frascino R. Epoetin alfa therapy for anaemia in HIV-infected patients: impact on quality of life. Int. J. STD AIDS, 2000, Vol. 11 (10), рр. 659–665.Abrams D.I., Steinhart C., Frascino R. Epoetin alfa therapy for anaemia in HIV-infected patients: impact on quality of life. Int. J. STD AIDS, 2000, Vol. 11 (10), рр. 659–665.Glaspy J.A., Chap L. The clinical application of recombinant erythropoietin in the HIV-infected patient. Hematol. Oncol. Clin. North Am., 1994, Vol. 8, рр. 945–957.Glaspy J.A., Chap L. The clinical application of recombinant erythropoietin in the HIV-infected patient. Hematol. Oncol. Clin. North Am., 1994, Vol. 8, рр. 945–957.Saag M.S., Bowers P., Leitz G.J. Once-weekly epoetin alfa improves quality of life and increases hemoglobin in anemic HIV+ patients. AIDS Res. Hum. Retroviruses, 2004, Vol. 20, рр. 1037–1045.Saag M.S., Bowers P., Leitz G.J. Once-weekly epoetin alfa improves quality of life and increases hemoglobin in anemic HIV+ patients. AIDS Res. Hum. Retroviruses, 2004, Vol. 20, рр. 1037–1045.Vansteenkiste J., Wauters I. The use of darbepoetin alfa for the treatment of chemotherapy-induced anaemia. Expert Opin. Pharmacother., 2005, Vol. 6 (3, рр. 429–440.Vansteenkiste J., Wauters I. The use of darbepoetin alfa for the treatment of chemotherapy-induced anaemia. Expert Opin. Pharmacother., 2005, Vol. 6 (3, рр. 429–440.Hoffman R., Benz E.J., Shattil S.J. Hematologic manifestations of AIDS. Hematology: Basic Principles and Practice. New York: Churchill Livingstone, 1995, рр. 2171–2200.Hoffman R., Benz E.J., Shattil S.J. Hematologic manifestations of AIDS. Hematology: Basic Principles and Practice. New York: Churchill Livingstone, 1995, рр. 2171–2200.Knowles D.M. Etiology and pathogenesis of AIDS-related non-Hodgkin’s lymphoma. Hematol. Oncol. Clin. North. Am., 1996, Vol. 10, рр. 1081–1109.Knowles D.M. Etiology and pathogenesis of AIDS-related non-Hodgkin’s lymphoma. Hematol. Oncol. Clin. North. Am., 1996, Vol. 10, рр. 1081–1109.Hermans P., Rozenbaum W., Jou A. Filgrastim to treat neutropenia and support myelosuppressive medication dosing in HIV infection. G-CSF 92105 Study Group. AIDS, 1996, Vol. 10 (14), рр. 1627–1633.Hermans P., Rozenbaum W., Jou A. Filgrastim to treat neutropenia and support myelosuppressive medication dosing in HIV infection. G-CSF 92105 Study Group. AIDS, 1996, Vol. 10 (14), рр. 1627–1633.Pitrak D.L. Filgrastim treatment of HIV-infected patients improves neutrophil function. AIDS, 1999, Vol. 13 (2), рр. 25–30.Pitrak D.L. Filgrastim treatment of HIV-infected patients improves neutrophil function. AIDS, 1999, Vol. 13 (2), рр. 25–30.Kuritzkes D.R. Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: the role of granulocyte colony-stimulating factor. Clin. Infect. Dis., 2000, Vol. 30 (2), рр. 256–260.Kuritzkes D.R. Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: the role of granulocyte colony-stimulating factor. Clin. Infect. Dis., 2000, Vol. 30 (2), рр. 256–260.Dubreuil-Lemaire M.L., Gori A., Vittecoq D. Lenograstim for the treatment of neutropenia in patients receiving ganciclovir for cytomegalovirus infection: a randomised, placebo-controlled trial in AIDS patients. Eur. J. Haematol., 2000, Vol. 65 (5), рр. 337–343.Dubreuil-Lemaire M.L., Gori A., Vittecoq D. Lenograstim for the treatment of neutropenia in patients receiving ganciclovir for cytomegalovirus infection: a randomised, placebo-controlled trial in AIDS patients. Eur. J. Haematol., 2000, Vol. 65 (5), рр. 337–343.Scadden D.T. The clinical applications of colony-stimulating factors in acquired immunodeficiency syndrome. Semin. Hematol., 1992, Vol. 29, рр. 33–37.Scadden D.T. The clinical applications of colony-stimulating factors in acquired immunodeficiency syndrome. Semin. Hematol., 1992, Vol. 29, рр. 33–37.Lyman G.H. Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action. Expert Opin. Biol. Ther., 2005, Vol. 5 (12), рр. 1635–1646.Lyman G.H. Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action. Expert Opin. Biol. Ther., 2005, Vol. 5 (12), рр. 1635–1646.Lieschke G.J., Burgess A.W. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N. Engl. J. Med., 1992, Vol. 327 (1), рр. 28–35.Lieschke G.J., Burgess A.W. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N. Engl. J. Med., 1992, Vol. 327 (1), рр. 28–35.Camino N., Nunez M., Blanco F., Gonzalez-Requena D., Gonzalez-Lahoz J., Soriano V. Indinavir-induced thrombocytopenia. AIDS Patient Care STD, 2003, Vol. 17, рр. 103–104.Camino N., Nunez M., Blanco F., Gonzalez-Requena D., Gonzalez-Lahoz J., Soriano V. Indinavir-induced thrombocytopenia. AIDS Patient Care STD, 2003, Vol. 17, рр. 103–104.Lebensztejn D.M., Kaczmarski M. Lamivudine-associatedthrombocytopenia. Am. J. Gastroenterol., 2002, Vol. 97, рр. 2687–2688.Lebensztejn D.M., Kaczmarski M. Lamivudine-associatedthrombocytopenia. Am. J. Gastroenterol., 2002, Vol. 97, рр. 2687–2688.Ramratnam B., Parameswaran J., Elliot B. Short course dexamethasone for thrombocytopenia in AIDS. Am. J. Med., 1996, Vol. 100, рр. 117–118.Ramratnam B., Parameswaran J., Elliot B. Short course dexamethasone for thrombocytopenia in AIDS. Am. J. Med., 1996, Vol. 100, рр. 117–118.Yap P.L., Todd A.A., Williams P.E. Use of intravenous immunoglobulin in acquired immune deficiency syndrome. Cancer, 1991, Vol. 68 (6), рр. 1440–1450.Yap P.L., Todd A.A., Williams P.E. Use of intravenous immunoglobulin in acquired immune deficiency syndrome. Cancer, 1991, Vol. 68 (6), рр. 1440–1450.Provan D., Stasi R., Newland A.C. et al. International consensus report on the investigation and management of primary immune thrombocyto- penia. Blood, 2010, Vol. 115 (2), рр. 168–186.Provan D., Stasi R., Newland A.C. et al. International consensus report on the investigation and management of primary immune thrombocyto- penia. Blood, 2010, Vol. 115 (2), рр. 168–186.Saleh M.N., Bussel J.B., Cheng G. Safety and effi of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood, 2013, Vol. 121 (3), рр. 537–545.Saleh M.N., Bussel J.B., Cheng G. Safety and effi of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood, 2013, Vol. 121 (3), рр. 537–545.US Food and Drug Administration. Promacta (eltrombopag): portal venous system thromboses in study of patients with chronic liver disease. May 12, 2010. URL: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm211796.htm (accessed March 18, 2013).US Food and Drug Administration. Promacta (eltrombopag): portal venous system thromboses in study of patients with chronic liver disease. May 12, 2010. URL: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm211796.htm (accessed March 18, 2013).

The authors declare that there are no conflicts of interest present.